vTv Therapeutics Inc. Class A Common Stock (VTVT)
Summary
vTv Therapeutics Highlights Cadisegliatin's Phase III Push to Tackle Type 1 Hypoglycemia
vTv Therapeutics NASDAQ: VTVT used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and review the development program for its investigational oral therapy, cadisegliatin.
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
vTv Therapeutics Inc. Class A Common Stock Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 148,314 | $3.48M | $3.88M | $397,763.06 | 11.43% |
| DRO Donal Reamonn O'Sullivan Brevan Howard Capital Management LP | 7,531 | $298,679 | $199,044.33 | -$99,634.67 | -33.36% |
 Point72 Asset Management LP Point72 Asset Management LP | 5,947 | $201,722.24 | $155,930.34 | -$45,791.9 | -22.7% |
 Sima Elimelech Activest Wealth Management | 50 | $883 | $1,307.5 | $424.5 | 48.07% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 45 | $779.4 | $1,193.85 | $414.45 | 53.18% |
vTv Therapeutics Inc. Class A Common Stock (VTVT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has vTv Therapeutics Inc. Class A Common Stock ever had a stock split?
vTv Therapeutics Inc. Class A Common Stock Profile
| Biotechnology Industry | Healthcare Sector | Paul J. Sekhri CEO | NASDAQ (CM) Exchange | 918385204 CUSIP |
| US Country | 26 Employees | - Last Dividend | 21 Nov 2023 Last Split | 30 Jul 2015 IPO Date |
Overview
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oral treatments for patients with diabetes. Since its inception in 2015, the company has been at the forefront of medical research in its field, focusing particularly on compounds that can be administered orally for ease of use and better patient compliance. Headquartered in High Point, North Carolina, vTv Therapeutics operates as a subsidiary under the umbrella of MacAndrews & Forbes Incorporated. Through strategic license and research agreements with several global pharmaceutical firms and institutions such as Reneo Pharmaceuticals, Inc., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S, vTv Therapeutics is expanding its reach and capabilities in various therapeutic areas related to diabetes and inflammatory diseases.
Products and Services
- TTP399: An innovative orally administered, small molecule designed as a liver-selective glucokinase activator. It specifically targets the treatment of type 1 diabetes. The drug aims to provide a new approach to managing this condition with an emphasis on safety and efficacy.
- HPP737: This compound serves as an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor. Its primary focus is on battling inflammatory diseases and psoriasis, offering a new route of treatment for patients seeking alternatives to current options.
- TTP273: A novel oral small molecule GLP-1 receptor agonist, TTP273 is developed to control postprandial glucose excursion, specifically catering to the needs of patients with cystic fibrosis-related diabetes. It represents a tailored approach to diabetes care in this unique patient population.
- HPP3033: As a non-electrophilic therapeutic option, HPP3033 activates the Nrf2 pathway to combat chronic diseases associated with oxidative stress. This exploratory treatment seeks to address a wide array of conditions with an underlying component of oxidative damage.
- Azeliragon: Targeting inflammatory lung diseases including severe COVID-19, alongside pancreatic and breast cancers, Azeliragon stands out as a RAGE antagonist. Its dual application in addressing both inflammatory and oncological conditions highlights its versatility and potential impact.
- HPP971: Another innovative approach in vTv Therapeutics’ arsenal, HPP971 seeks to harness the power of Nrf2 activation. This Nrf2 activator is designed for the treatment of disorders where oxidative stress plays a critical role in disease progression.
Contact Information
